Loading
Life sciences · Journal article
Clinical and Preventive Medicine · October 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction. The European MDS Study Group reported a deterioration in quality of life in patients with myelodysplastic syndrome (MDS) compared with controls without MDS. In turn, despite advances in supportive care, survival in acute myeloid leukemia (AML) and other high-risk myeloid neoplasms is often measured in months rather than years, and long-term management usually requires polychemotherapy with allogeneic hematopoietic cell transplantation. However, relatively few studies on AML to date have included quality of life measurements. Aim. To study and evaluate individual and integrated indicators of quality of life in patients with MDS and AML. Materials and methods. Clinical monitoring of two groups of patients was conducted. Patients in group 1 (MDS, n=30), who underwent conventional therapy according to guideline No. 00327, filled out the MDS-specific quality of life assessment scale (QUALMS) at the beginning of treatment and after 12 weeks. Patients in the second group (AML, n=30), who received therapy according to guideline No. 1873 dated 10/30/2023, were offered to fill out the EORTC QLQ-C30 questionnaire – a widely used tool for determining the level of quality of life for cancer patients. Results. In patients with MDS before the start of the treatment protocol, the vast majority of individual results after filling out the QUALMS questionnaire did not exceed 55.0 points. However, after 12 weeks, the integrated quality of life index showed an increase to 65.9±4.6 points, which is an average of 21.3% higher than the initial result, p<0.05. In patients with AML, the vast majority of individual results according to the EORTC QLQ-C30 questionnaire reached 66.0 points, and the integrated quality of life index was at the level of 62.9±7.8 points. After treatment, the results in most questionnaires reached values of 69.0–84.0 points, and the integrated quality of life index was 78.1±8.0 points, which exceeded the initial level by 19.7%. Conclusions. In patients with MDS and AML undergoing conventional therapy, there is a significant potential for improving quality of life, which is confirmed by the increase in satisfactory results according to the QUALMS and EORTC QLQ-C30 questionnaires.